Dapagliflozin Influences Ventricular Hemodynamics and Exercise-Induced Pulmonary Hypertension in Type 2 Diabetes Patients　― A Randomized Controlled Trial ―-Reference-Cited by-同舟云学术

Dapagliflozin Influences Ventricular Hemodynamics and Exercise-Induced Pulmonary Hypertension in Type 2 Diabetes Patients　― A Randomized Controlled Trial ―

Published:2020-09-25 Issue:10 Volume:84 Page:1807-1817
ISSN:1346-9843
Container-title:Circulation Journal
language:en
Short-container-title:Circ J

Author:

Kayano Hiroyuki¹,Koba Shinji¹,Hirano Tsutomu²,Matsui Taiju¹,Fukuoka Hiroto¹,Tsuijita Hiroaki¹,Tsukamoto Shigeto¹,Hayashi Toshiyuki²,Toshida Tsutomu¹,Watanabe Norikazu¹,Hamazaki Yuji¹,Geshi Eiichi³,Murakami Mikitaka⁴,Aihara Kazuo⁵,Kaneko Koujin⁶,Yamada Hirokazu⁷⁸,Kobayashi Youichi¹,Shinke Toshiro¹

Affiliation:

1. Department of Medicine, Division of Cardiology, Showa University School of Medicine

2. Department of Medicine, Division of Diabetes, Metabolism and Endocrinology, Showa University School of Medicine

3. Department of Internal Medicine, Showa University School of Nursing and Rehabilitation Sciences

4. Murakami Cardiology and Medical Clinic

5. Aihara Medical Clinic

6. Kaneko Clinic

7. Soiken Inc.

8. EviPRO Co., Ltd.

Publisher

Japanese Circulation Society

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://www.jstage.jst.go.jp/article/circj/84/10/84_CJ-20-0341/_pdf

Reference32 articles.

1. 1. Vazquez-Benitez G, Desai JR, Xu S, Goodrich GK, Schroeder EB, Nichols GA, et al. Preventable major cardiovascular events associated with uncontrolled glucose, blood pressure, and lipids and active smoking in adults with diabetes with and without cardiovascular disease: A contemporary analysis. Diabetes Care 2015; 38: 905–912.

2. 2. Paulus WJ, Tschöpe C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, et al. How to diagnose diastolic heart failure: A consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007; 28: 2539–2550.

3. 3. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117–2128.

4. 4. Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin for primary and secondary prevention of cardiovascular events: Results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation 2018; 137: 323–334.

5. 5. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2018; 373: 2117–2128.

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Heart Failure in Patients With Type 2 Diabetes Mellitus: A Systematic Review;Cureus;2024-09-03

2. Influence of Dapagliflozin Dosing on Low‐Density Lipoprotein Cholesterol in Type 2 Diabetes Mellitus: A Systematic Literature Review and Meta‐Analysis;The Journal of Clinical Pharmacology;2024-08

3. Pulmonary hypertension associated to left heart disease: Phenotypes and treatment;European Journal of Internal Medicine;2024-08

4. Plasma Proteomics Identifies B2M as a Regulator of Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction;Arteriosclerosis, Thrombosis, and Vascular Biology;2024-07

5. SGLT2 inhibitors as a potential therapeutic option for pulmonary hypertension: mechanisms and clinical perspectives;Critical Reviews in Clinical Laboratory Sciences;2024-06-07